BiovaxID given orphan designation for Waldenstrom’s

Submitted by Ross Bonander Thu 10/27/2011

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Biovest International, Inc. (owned by Accentia Biopharmaceuticals) has announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's lead oncology candidate, BiovaxID, for a rare subtype of non-Hodgkin's lymphoma.

BiovaxID is autologous active immunotherapy—a personalized cancer vaccine, in other words—that Biovest has been working on for several years and which has been developed by Dr. Larry Kwak, Chairman of the Department of Lymphoma/Myeloma at the MD Anderson Cancer Center in Houston, Texas.

The subtype is Waldenstrom’s macroglobulinemia, an indolent B-cell non-Hodgkin's lymphoma that is typically treated with single-agent chemotherapy involving alkylating agents (such as chlorambucil), multiagent chemotherapy (involving vincristine, cyclophosphamide, and prednisone, with or without anthtacyclines), or possibly fludarabine.

Biovest's longer term aim is to receive FDA market approval for BiovaxID for the treatment of follicular lymphoma.

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.